<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04638491</url>
  </required_header>
  <id_info>
    <org_study_id>LY01017/CT-CHN-101</org_study_id>
    <nct_id>NCT04638491</nct_id>
  </id_info>
  <brief_title>Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients</brief_title>
  <official_title>Phase 1, Single-arm, Open-label, Dose Escalating and Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of Lurbinectedin (PM01183) for Injection in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luye Pharma Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luye Pharma Group Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, single-arm, open-label, dose escalating and expansion clinical trial to evaluate the&#xD;
      safety, tolerability, pharmacokinetic and preliminary efficacy of Lurbinectedin (PM01183) for&#xD;
      injection in patients with advanced solid tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and tolerability of PM01183 as a single agent, and to identify the&#xD;
      dose limiting toxicities (DLTs), determine the recommended dose (RD) in Chinese advanced&#xD;
      solid tumors patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 26, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Lurbinectedin for injection(PM01183)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>From date of first administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months(each cycle is 21 days)</time_frame>
    <description>The number and percentage of subjects with significant remission (CR + PR) were calculated, and the 95% confidence interval of the percentage was calculat</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>From date of first administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months(each cycle is 21 days)</time_frame>
    <description>The number and percentage of subjects with disease control (CR+PR+SD) were calculated, and the 95% confidence interval of the percentage was calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>From date of first administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months(each cycle is 21 days)</time_frame>
    <description>Survival analysis (Kaplan Meier method) was used to estimate the median dor and its 95% confidence interval (CI), and the K-M curve was drawn</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>From date of first administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months(each cycle is 21 days)</time_frame>
    <description>Survival analysis (Kaplan Meier method) was used to estimate the median dor and its 95% confidence interval (CI), and the K-M curve was drawn</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR)</measure>
    <time_frame>From date of first administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months(each cycle is 21 days)</time_frame>
    <description>Survival analysis (Kaplan Meier method) was used to estimate the median dor and its 95% confidence interval (CI), and the K-M curve was drawn</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>single-arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PM01183-Dose Escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurbinectedin for injection</intervention_name>
    <description>On the first day of each cycle, patients with advancedsolid tumors or small cell lung cancer were treated with Lurbinectedin for injection</description>
    <arm_group_label>single-arm</arm_group_label>
    <other_name>PM01183</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Voluntary written informed consent of the patient.&#xD;
&#xD;
          -  2. Age≥18 years.&#xD;
&#xD;
          -  3. Escalating stage: Patients with histologically/cytologically confirmed diagnosis of&#xD;
             advanced solid tumors refractory to standard therapy or for whom refuses or cannot&#xD;
             tolerate standard treatment or no standard therapy exist (no more than three prior&#xD;
             regimens for advanced or unresectable disease).&#xD;
&#xD;
          -  4. Expansion stage: Patients with histologically confirmed diagnosis of advanced or&#xD;
             unresectable SCLC who had failure to one prior platinum -containing line.&#xD;
&#xD;
          -  5. Measurable disease as defined by the RECIST v.1.1.&#xD;
&#xD;
          -  6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.&#xD;
&#xD;
          -  7. Life expectancy ≥3 months.&#xD;
&#xD;
          -  8. Adequate bone marrow, renal, hepatic, and metabolic function as follows: Platelet&#xD;
             count ≥ 100 x 109/l, Hemoglobin ≥ 90 g/l, absolute neutrophil count (ANC) ≥ 2.0 x&#xD;
             109/l; Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 3.0 x&#xD;
             upper limit of normal (ULN), ≤ 5.0 x ULN if presence of liver metastases; Alkaline&#xD;
             phosphatase ≤ 5.0 x ULN ; Total bilirubin ≤ 1.5 x ULN, and direct bilirubin ≤1 x ULN ;&#xD;
             Serum creatinine ≤ 1.5 x ULN or Calculated creatinine clearance: ≥ 30 ml/min&#xD;
             (calculated using the Cockcroft and Gault formula); Creatine phosphokinase (CPK) ≤ 2.5&#xD;
             x ULN; Albumin ≥ 3 g/dl.&#xD;
&#xD;
          -  9. Recovery to grade ≤ 1 according to the NCI-CTCAE v.5.0, of any ongoing adverse&#xD;
             event derived from previous treatment ( with the exception of grade 2 alopecia and&#xD;
             non-painful peripheral sensory neuropathy ).&#xD;
&#xD;
          -  10. Women of childbearing potential must have a negative serum pregnancy test before&#xD;
             study entry. Women of childbearing potential must agree to use a medically acceptable&#xD;
             method of contraception throughout the treatment period and for 6 months after&#xD;
             discontinuation of treatment. Male patients (female partners is of childbearing&#xD;
             potential ) take effective contraceptive measures throughout the treatment period and&#xD;
             for 4 months after discontinuation of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Prior treatment with trabectedin.&#xD;
&#xD;
          -  2. Patients with brain metastases, a history of spinal cord compression, or meningeal&#xD;
             metastases.&#xD;
&#xD;
          -  3. Suspected or confirmed disease bone marrow involved.&#xD;
&#xD;
          -  4. Bone metastases, obstructive atelectasis, superior vena cava syndrome patients with&#xD;
             local symptoms that may require radiotherapy/surgery/endoscopic&#xD;
             treatment/interventional intervention; patients with suspected or confirmed pulmonary&#xD;
             embolism; uncontrollable large amounts of pleural fluid, ascites and pericardial&#xD;
             effusion.&#xD;
&#xD;
          -  5. Patients who received other recent antitumor therapies ( with respect to study&#xD;
             treatment start ) : Less than three weeks since the last chemotherapy-containing&#xD;
             regimen (six weeks in case of nitrosoureas, mitomycin C ).&#xD;
&#xD;
        Less than four weeks since the last monoclonal antibody-containing therapy or radiotherapy&#xD;
        (RT) dose &gt;30 Gy.&#xD;
&#xD;
        Less than two weeks since the last any other biological/investigational anticancer therapy&#xD;
        or palliative radiotherapy ( total dose ≤30 Gy).&#xD;
&#xD;
          -  6. Concomitant diseases/conditions: History (during the last year) or presence of any&#xD;
             of the following: unstable angina, myocardial infarction, New York Heart Association&#xD;
             (NYHA) Class II or greater congestive heart failure (CHF), or clinically significant&#xD;
             valvular heart disease; History of stroke within 1 year (including ischemic stroke,&#xD;
             hemorrhagic stroke); Patients with uncontrolled hypertension (systolic blood pressure&#xD;
             greater than 160 mmHg and/or diastolic blood pressure greater than 100 mmHg); History&#xD;
             of hypertensive crisis or hypertensive encephalopathy; Severe arrhythmia requiring&#xD;
             ongoing pharmacological treatment; Positive tests for Hepatitis B surface antigen&#xD;
             (HBsAg) and the peripheral blood hepatitis B virus deoxyribonucleic acid (HBV DNA)&#xD;
             titer test is ≥1×103 copies/mL; if the HBsAg is positive, and the peripheral blood HBV&#xD;
             DNA titer test is &lt;1×103 copies/ml and in the Investigator's judgment, the patient is&#xD;
             under a stable stage of chronic hepatitis B and does not increase the risk of the&#xD;
             patient, then the patient is eligible for selection; HCV antibody positive or HIV&#xD;
             antibody positive; Active uncontrolled infection requiring ongoing medical treatment&#xD;
             within two weeks prior to treatment start.&#xD;
&#xD;
        Evidence of bleeding diathesis or significant coagulopathy; Prior or concurrent invasive&#xD;
        malignancy other than the primary study indication within 5 years prior to treatment start,&#xD;
        except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin&#xD;
        cancer, local prostate cancer after radical resection, and ductal carcinoma in situ after&#xD;
        radical resection； Any other major illness that, in the Investigator's judgment, not&#xD;
        suitable for inclusion in this study.&#xD;
&#xD;
          -  7. History of previous bone marrow and/or stem cell transplantation.&#xD;
&#xD;
          -  8. Prior medication requirements: Patients who have used strong inducers or inhibitors&#xD;
             of cytochrome P450 3A4 enzyme (CYP3A4) within 2 weeks or 5 half-lives ( whichever is&#xD;
             longer ) prior to treatment start; Prophylaxis or treatment for non-febrile&#xD;
             neutropenia with G-CSF within two weeks prior to treatment start; Patients who have&#xD;
             used erythropoietin and derivatives within 3 weeks prior to treatment start; Patients&#xD;
             who have used blood transfusions within 2 weeks prior to treatment start.&#xD;
&#xD;
          -  9. Patients who may need to receive other systemic anti-tumor or radical treatments&#xD;
             for local target/non-target lesions during the study period;&#xD;
&#xD;
          -  10. Known history of psychotropic drug, alcohol or drug abuse;&#xD;
&#xD;
          -  11. Known to be allergic to any component of the investigational drug;&#xD;
&#xD;
          -  12. Pregnant or breastfeeding women, or women of childbearing potential have a&#xD;
             positive blood pregnancy test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>cheng ying, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jilin Provincial Tumor Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>wu chunjiao, Doctor</last_name>
    <phone>18643112151</phone>
    <email>2956519672@.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>xing juying, bachelor</last_name>
    <phone>13039116978</phone>
  </overall_contact_backup>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lurbinectedin(PM01183) for injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

